Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen

被引：0
|
作者：
Bubalo, Joseph [1 ]
Chen, Andy I. [2 ]
Leong, Kelli [3 ]
Gille, Bianca [4 ]
Nagle, Sarah [5 ]
Bensch, Kenneth [4 ]
Macey, Tara [4 ]
Ellison, Kelly [4 ]
Booth, Georgeann [4 ]
Misra, Shikha [4 ]
Maziarz, Richard T. [6 ]
机构：
[1] Oregon Hlth & Sci Univ Hosp, Pharm Serv, CR 9-4, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ Hosp, Pharm, Portland, OR USA
[4] Oregon Hlth & Sci Univ Hosp, Portland, OR USA
[5] Oregon Hlth & Sci Univ Hosp, Portland, PA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
414
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study
    Schilling, Joerg
    Busch, Steffi
    Stefek, Andrea
    Muller, Eberhard
    Schwickerath, Juergen
    Altmann, Falk
    Hollander, Martin
    Karthaus, Meinolf
    CANCER RESEARCH, 2020, 80 (04)
  • [42] Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
    Joseph S. Bubalo
    Jon D. Herrington
    Marc Takemoto
    Patricia Willman
    Michael S. Edwards
    Casey Williams
    Alan Fisher
    Alison Palumbo
    Eric Chen
    Charles Blanke
    Charles D. Lopez
    Supportive Care in Cancer, 2018, 26 : 1273 - 1279
  • [43] Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
    Bubalo, Joseph S.
    Herrington, Jon D.
    Takemoto, Marc
    Willman, Patricia
    Edwards, Michael S.
    Williams, Casey
    Fisher, Alan
    Palumbo, Alison
    Chen, Eric
    Blanke, Charles
    Lopez, Charles D.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (04) : 1273 - 1279
  • [44] Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting
    Lorusso, Vito
    Karthaus, Meinolf
    Aapro, Matti
    FUTURE ONCOLOGY, 2015, 11 (04) : 565 - 577
  • [45] Efficacy and Safety of Palonosetron Versus Ondansetron in Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children
    Chaudhary, N.
    Boddu, D.
    John, R. R.
    Gowri, M. S.
    Nesadeepam, W. N.
    Mathew, L. G.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S17 - S17
  • [46] Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting
    Ma, Yuan
    Su, Lei
    Liu, Liyan
    Xie, Chao
    Zhang, Xia
    Song, Bao
    Cheng, Sensen
    Liu, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7989 - 7994
  • [47] Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Efficacy of an intravenous formulation of NEPA, a fixed combination of fosnetupitant and palonosetron, compared with oral NEPA studies in the prevention of chemotherapy-induced nausea and vomiting (CINV): An analysis of 1026 patient experiences.
    Roeland, Eric
    Hesketh, Paul Joseph
    Zhang, Li
    Gralla, Richard J.
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    Gralla, R. J.
    Bosnjak, S. M.
    Hontsa, A.
    Balser, C.
    Rizzi, G.
    Rossi, G.
    Borroni, M. E.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339
  • [50] Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
    Simhadri, Soumya
    Dayyala, Sowmya
    Musinipally, Anjani Devi
    Guram, Lavanya
    Madavi, Mamatha
    Kancha, Ramakrishna
    Puligundla, Krishna Chaitanya
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
12345